Alternative COVID vaccine 75% cross-protective against symptomatic cases in previously infected-- study

Trial: Alternative COVID vaccine 75% cross-protective against symptomatic cases in previously infected USAID/Rwanda / Flickr cc CIDRAP

A phase 3 randomized, controlled trial in adults in eight countries concludes that a protein-based vaccine targeting both the wild-type and Beta SARS-CoV-2 spike proteins is an estimated 75.1% effective against symptomatic COVID-19 among previously infected people and 30.9% among those never-infected amid Omicron variant predominance.

The researchers said the findings, published yesterday in The Lancet Respiratory Medicine, suggest that vaccines developed with an antigen from a non-dominant SARS-CoV-2 strain can provide cross-protection against newer variants.

...